Invention Grant
US07879868B2 Use of imatinib (glivec,sti-571) to inhibit breast cancer resistance protein (BCRP)-mediated resistance to therapeutic agents
失效
使用伊马替尼（glivec，sti-571）抑制乳腺癌抗性蛋白（BCRP）介导的治疗剂抗性
- Patent Title: Use of imatinib (glivec,sti-571) to inhibit breast cancer resistance protein (BCRP)-mediated resistance to therapeutic agents
- Patent Title (中): 使用伊马替尼（glivec，sti-571）抑制乳腺癌抗性蛋白（BCRP）介导的治疗剂抗性
-
Application No.: US10530618Application Date: 2003-10-10
-
Publication No.: US07879868B2Publication Date: 2011-02-01
- Inventor: Peter J. Houghton , Peter Traxler
- Applicant: Peter J. Houghton , Peter Traxler
- Applicant Address: CH Basel
- Assignee: Novartis AG
- Current Assignee: Novartis AG
- Current Assignee Address: CH Basel
- Agency: Dilworth & Barrese, LLP
- Agent Ann R. Pokalsky, Esq.
- International Application: PCT/EP03/11271 WO 20031010
- International Announcement: WO2004/032925 WO 20040422
- Main IPC: A01N43/54
- IPC: A01N43/54 ; A01N43/42 ; A61K31/505 ; A61K31/44
Abstract:
The present invention relates to the use of imatinib of the following formula or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for the treatment of a cancer that expresses breast cancer resistant protein (BCRP) in a human subject in need of such a treatment.
Public/Granted literature
Information query
IPC分类:
